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The goal of Mass Spectrometry in Medicinal Chemistry:
Applications in Drug Discovery is to describe the intimate
relationship between bioanalytical mass spectrometry
(MS) and the drug discovery process. The authors have
assembled a fine collection that I thoroughly enjoyed
reading.
The book is part of the series in Methods and
Principles in Medicinal Chemistry from Wiley-VCH,
edited by Raimund Mannhold, Hugo Kubinyi, and
Gerd Folkers. As the editors point out, the importance
of mass spectrometry in the drug discovery arena has
been “largely unperceived” by medicinal chemists over
the last twenty or so years. The collection of articles
covers lead discovery and optimization using modern
applications of mass spectrometry, reflecting the very
real impact this technology has brought to bear on the
central function of drug discovery. The book itself is
edited by Klaus Wanner and Georg Höfner of the
Center of Drug Research at the Ludwig-Maximilians-
University in Munich. Both are actively engaged in
research, most recently focusing on compounds that
target neurotransmitter receptors, and they have been
leading proponents of mass spectrometry in medicinal
chemistry for several years.
Although a quick search of amazon.com reveals
several thousand titles focused on medicinal chemistry,
less than a handful discuss the application of mass
spectrometry in this arena. There are so many applica-
tions of mass spectrometry in biological chemistry that
it will be most useful for medicinal chemists to have
their own dedicated collection of articles assembled
here in Mass Spectrometry in Medicinal Chemistry.
The book is organized into thirteen chapters with the
first providing an introduction and subsequent chapters
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(J Am Soc Mass Spectrom 2008, 19, R1–R2)detailing specific applications in use today as part of the
drug discovery effort, subdivided into four subheadings;
studying target–ligand interactions by analyzing the li-
gand alone, by analyzing target–ligand complexes, or by
studying the target-binding site by MS, as well as a final
chapter dealing with MS in early pharmacokinetics.
Chapter 1 (“Mass Spectrometry in Bioanalysis: Meth-
ods, Principles and Instrumentation”) is necessarily
brief and covers the basics of MS as it relates to analysis
of biomolecules. The text reads well and is generally
consistent with the msterms.com list of definitions,
bringing me to my only significant criticism. The
opening paragraph of the fundamentals section has
the potential to confuse, as a result of the need to
accurately educate the reader while avoiding lengthy
explanation. This is a minor point and the text moves
nicely through ionization, mass analyzers, and detec-
tors and then ends up with brief descriptions of
quantitative analysis, drug metabolism, and protein/
peptide analysis, providing a necessary introduction
for the coming chapters.
The “meat” of this tome is found in section II with
seven substantial chapters on “studying target–ligand
interactions analyzing the ligand by MS” covering the
major methodologies used by the pharmaceutical in-
dustry for high-throughput screening. Marshall Siegel
from Wyeth Research describes the theory and practice
of “Drug Screening Using Gel Permeation Chromatog-
raphy Spin Columns Coupled with ESI-MS.” Molecules
that bind a target protein are swept through the column
rapidly, whereas those that do not are retained. Both
theory and practical details are covered, and there are
many illustrations of relevant examples throughout.
The chapter that follows by Allen Annis, Cheng-Chi
Chuang, and Naim Nazef at Schering-Plough describes
“ALIS: An Affinity Selection–Mass Spectrometry Sys-
tem for the Discovery and Characterization of Protein–
Ligand Interactions.” Rapid size-exclusion chromatog-
raphy is used to separate ligand–protein complexes, as
described in the previous chapter, with a downstream
reverse-phase chromatography step to separate the li-
gand from the protein. There is again consideration of
theory, and many examples are used to illustrate the
versatility of the system.
In chapter 4, Timothy Cloutier and Kenneth Comess
at Abbott Labs describe “Library Screening Using
Ultrafilitration and Mass Spectrometry.” The approach
is similar to that described in the previous two chapters
with the major difference that ultrafiltration is used to
separate the protein-bound ligand from the unbound
ligand. This is a shorter chapter that focuses on the
practical experiences of the authors and nicely comple-
ments the preceding chapters.
Chapter 5 is written by Hubertus Irth at Vrije Uni-
versiteit Amsterdam and describes “Continuous-flow
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Assays Based on Mass Spectrometry.” Mass spectrom-
etry is used to monitor substrate and product concen-
trations from an enzyme reactor such that introduction
of an inhibitor results in perturbation of these signals.
The complexity of the setup is offset by the advantage
that actual inhibition of function is measured in distinc-
tion to simple binding.
Chapter 6 is by David Schreimer and colleagues at
the University of Calgary and describes “Frontal Affin-
ity Chromatography—Mass Spectrometry for Ligand
Discovery and Characterization.” I have always found
FAC-MS particularly elegant after hearing about it from
David at one of the ASMS Asilomar meetings. Mass
spectrometry is used to monitor the appearance of
freshly introduced small molecules as they flow through a
column of immobilized receptor with the appearance of
ligand molecules delayed as they partition to an immo-
bile bound state. The chapter is very well written and
explains the exact place for FAC-MS in the drug dis-
covery field, able to cope with quite complex mixtures
of poorly defined molecules such as natural product
extracts.
Chapter 7 is contributed by the editors and describes
the use of “MS Binding Assays—An Alternative to
Radioligand Binding.” Quantitative mass spectrometry
is used to measure either unbound or bound ligands
after incubation with a receptor. The chapter is very
clear and well illustrated with many examples from the
neurotransmitter receptor field.
The final chapter (8) of this section written by Martin
Vogel, Andy Scheffer, Andre Liesener, and Uwe Karst
describes “Laser Desorption Assays–MALDI-MS, DIOS-MS
and SAMDI-MS.” Although the rest of this section
focused on applications of ESI-MS, this one covers
laser desorption techniques that are in their infancy
in this analytical realm. The authors do a concise job
of describing progress and illustrating potential for
the future.
Section III of the book has two chapters describing
direct analysis of target–ligand complexes by mass
spectrometry. The first of these written by Mark
Cancilla and Daniel Erlanson of Sunesis Pharmaceu-
ticals and describes “Tethering: Fragment-based
Drug Discovery by Mass Spectrometry.” This ap-
proach was developed because of the difficulties in
detecting low-affinity binding to targets; an engi-
neered tether is used covalently link the target to the
ligand upon weak binding for downstream identifi-
cation by mass spectrometry. The Sunesis strategy is
described concisely.In the next chapter (10) Steven Hofstadler and Kris-tin Sannes-Lowery of Isis Pharmaceuticals describe “In-
terrogation of Noncovalent Complexes by ESI-MS: A
Powerful Platform for High Throughput Drug Discov-
ery.” This is a relatively brief but enjoyable account of
the authors’ considerable experience performing ESI-MS
under non-denaturing conditions that retain structure
and non-covalent binding of ligands.
Section IV of the book again has two chapters, this
time describing how protein hydrogen/deuterium ex-
change measurements (HDX) can be used to study
target-binding sites. First, Mei Zhu, David Hambley,
and Michael Gross of Washington University describe
“Quantification of Protein–Ligand Interactions in Solu-
tion by Hydrogen/Deuterium Exchange (PLIMSTEX).”
The chapter also includes a section on fast radical-
footprinting for protein–ligand interaction analysis
(FPOP)—a technique that is poised to deliver important
and complementary insights into the protein–ligand
interaction.
Second, Yoshitomo Hamuro, Stephen Coales, and
Virgil Woods of UCSD describe “Protein-targeting
Drug Discovery Guided by Hydrogen/Deuterium Ex-
hange Mass Spectrometry (DXMS).” This chapter gives
a concise overview of the contribution HDX measure-
ments can make to the drug discovery process and a
thorough introduction to the work in this area at UCSD.
The two chapters combined make for very thorough
coverage of HDX mass spectrometry and its role in
studying protein–ligand interactions.
The final section of the book on “Mass Spectrometry in
Early Pharmacokinetic Investigations” has a single chap-
ter written by Walter Korfmacher at Schering-Plough.
This chapter rounds out the book nicely, highlighting the
role of mass spectrometry in events after a lead is identi-
fied toward the definition of a new chemical entity that
will move successfully through clinical trials.
Overall, Mass Spectrometry in Medicinal Chemistry is
an excellent choice not only for young scientists enter-
ing the drug discovery field, but also for established
mass spectrometrists interested in understanding appli-
cations that are developing in diverse fields. From a
personal perspective, I found nearly all of the chapters
especially illuminating because of their focus on the
high-throughput needs of the field. Hopefully, this
underlying theme will help to educate readers as to
how basic technology gets driven in exciting yet some-
what unpredictable directions by commercial forces.
Despite being priced a little on the high side ($200 US),
I believeMass Spectrometry in Medicinal Chemistry is still
an excellent value and should be required reading,
particularly for the growing population of young scien-
tists joining the field of mass spectrometry.
